open access

Vol 12, No 4 (2017)
Heart failure
Published online: 2017-09-19
Get Citation

Komentarz

Jadwiga Nessler
Folia Cardiologica 2017;12(4):405-407.

open access

Vol 12, No 4 (2017)
Heart failure
Published online: 2017-09-19

Abstract

Not available

Abstract

Not available
Get Citation
About this article
Title

Komentarz

Journal

Folia Cardiologica

Issue

Vol 12, No 4 (2017)

Pages

405-407

Published online

2017-09-19

Bibliographic record

Folia Cardiologica 2017;12(4):405-407.

Authors

Jadwiga Nessler

References (10)
  1. Rywik TM, Kołodziej P, Targoński R, et al. Characteristics of the heart failure population in Poland: ZOPAN, a multicentre national programme. Kardiol Pol. 2011; 69(1): 24–31.
  2. Gierczynski J, Gryglewicz J, Karczewicz E, Zalewska H. Niewydolność serca — analiza kosztów ekonomicznych i społecznych. Uczelnia Łazarskiego, Warszawa 2013.
  3. Health at a Glance 2015. OECD indicators. OECD Publishing, Paris 2015. http://www.health.gov.il/publicationsfiles/healthataglance2015.pdf.
  4. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Rev Esp Cardiol (Engl Ed). 2016; 69(12): 1167.
  5. McMurray JJV, Packer M, Desai AS, et al. PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014; 371(11): 993–1004.
  6. Packer M, McMurray JJV, Desai AS, et al. PARADIGM-HF Investigators and Coordinators. Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation. 2015; 131(1): 54–61.
  7. Solomon SD, Dobson J, Pocock S, et al. Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) Investigators. Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation. 2007; 116(13): 1482–1487.
  8. Senni M, McMurray JJV, Wachter R, et al. Initiating sacubitril/valsartan (LCZ696) in heart failure: results of TITRATION, a double-blind, randomized comparison of two uptitration regimens. Eur J Heart Fail. 2016; 18(9): 1193–1202.
  9. Vardeny O, Claggett B, Packer M, et al. Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Investigators. Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM-HF trial. Eur J Heart Fail. 2016; 18(10): 1228–1234.
  10. Straburzyńska-Migaj E, Nessler J, Gruchała M, et al. Sacubitril/valsartan for treatment of chronic heart failure with reduced ejection fraction. Can all patients benefit? A position statement paper of experts of the Heart Failure Working Group of the Polish Cardiac Society. Kardiol Pol. 2017; 75(3): 286–293.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

 

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl